ATE549404T1 - Verfahren zum screening eines transmembranenzymhemmstoffs - Google Patents

Verfahren zum screening eines transmembranenzymhemmstoffs

Info

Publication number
ATE549404T1
ATE549404T1 AT05790422T AT05790422T ATE549404T1 AT E549404 T1 ATE549404 T1 AT E549404T1 AT 05790422 T AT05790422 T AT 05790422T AT 05790422 T AT05790422 T AT 05790422T AT E549404 T1 ATE549404 T1 AT E549404T1
Authority
AT
Austria
Prior art keywords
transmembrane
enzyme
protein
region
inhibitor
Prior art date
Application number
AT05790422T
Other languages
English (en)
Inventor
Naoki Tarui
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE549404T1 publication Critical patent/ATE549404T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478Aspartic endopeptidases (3.4.23)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/914Hydrolases (3)
    • G01N2333/948Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96472Aspartic endopeptidases (3.4.23)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT05790422T 2004-10-01 2005-09-30 Verfahren zum screening eines transmembranenzymhemmstoffs ATE549404T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004290784 2004-10-01
PCT/JP2005/018587 WO2006038684A1 (ja) 2004-10-01 2005-09-30 膜貫通型酵素阻害物質のスクリーニング方法

Publications (1)

Publication Number Publication Date
ATE549404T1 true ATE549404T1 (de) 2012-03-15

Family

ID=36142754

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05790422T ATE549404T1 (de) 2004-10-01 2005-09-30 Verfahren zum screening eines transmembranenzymhemmstoffs

Country Status (5)

Country Link
US (1) US20080220445A1 (de)
EP (1) EP1801232B1 (de)
JP (1) JP4778906B2 (de)
AT (1) ATE549404T1 (de)
WO (1) WO2006038684A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2638070B1 (de) 2010-11-10 2016-10-19 F.Hoffmann-La Roche Ag Verfahren und zusammensetzungen zur immuntherapie bei nervenerkrankungen
WO2016081640A1 (en) 2014-11-19 2016-05-26 Genentech, Inc. Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
US10882920B2 (en) 2014-11-19 2021-01-05 Genentech, Inc. Antibodies against BACE1 and use thereof for neural disease immunotherapy
CN107523579A (zh) * 2017-09-08 2017-12-29 东北师范大学 促进大脑中Aβ累积的BACE1亚型的功能研发及应用
CN107475260B (zh) * 2017-09-08 2020-12-04 东北师范大学 抑制大脑中Aβ累积的BACE1亚型的功能研发及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0667959T3 (da) 1992-10-26 2003-12-08 Elan Pharm Inc Fremgangsmåder til identificering af inhibitorer af produktionen af beta-amyloidpeptid
CZ184194A3 (en) 1993-08-09 1995-03-15 Lilly Co Eli Aspartylprotease inhibitor and method of identifying thereof
CA2321962C (en) * 1998-02-27 2014-07-15 The Government Of The United States Of America, Represented By The Secretary Of The Department Of Health And Human Services G protein-coupled receptor antagonists
US6699671B1 (en) * 1998-09-24 2004-03-02 Pharmacia & Upjohn Company Alzheimer's disease secretase, APP substrates therefor, and uses therefor
WO2000024780A2 (en) 1998-10-26 2000-05-04 Genzyme Corporation Compositions and methods for treating polycystic kidney disease
US20040110743A1 (en) * 2000-05-19 2004-06-10 Masaomi Miyamato -Secretase inhibitors
JP2002037731A (ja) * 2000-05-19 2002-02-06 Takeda Chem Ind Ltd βセクレターゼ阻害剤
US20030095958A1 (en) 2001-04-27 2003-05-22 Bhisetti Govinda R. Inhibitors of bace
US6562783B2 (en) * 2001-05-30 2003-05-13 Neurologic, Inc. Phosphinylmethyl and phosphorylmethyl succinic and glutauric acid analogs as β-secretase inhibitors
CH698246B1 (de) 2001-12-20 2009-06-30 Hoffmann La Roche Test zur Identifizierung von Inhibitoren von Beta-Sekretasen.
EP1459764A4 (de) * 2001-12-26 2006-08-16 Takeda Pharmaceutical Mittel zur behandlung von leichten erkennungsstörungen

Also Published As

Publication number Publication date
EP1801232A4 (de) 2008-12-10
JP4778906B2 (ja) 2011-09-21
EP1801232B1 (de) 2012-03-14
US20080220445A1 (en) 2008-09-11
WO2006038684A1 (ja) 2006-04-13
JPWO2006038684A1 (ja) 2008-05-15
EP1801232A1 (de) 2007-06-27

Similar Documents

Publication Publication Date Title
ATE496021T1 (de) Kristalline formen von (-)-(1r,2r)-3-(3- dimethylamino-1-ethyl-2-methylpropyl)- phenolhydrochlorid zur verwendung als aktivstoff in pharmazeutischen zubereitungen
EA200100992A1 (ru) Ингибиторы фермента impdh
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
WO2005082343A3 (en) Amines and amides for the treatment of diseases
ATE556711T1 (de) Verfahren zur verbesserung der hautqualität
CY1108689T1 (el) Ολιγοπεπτιδια για την ελαττωση αυξημενης συγκεντρωσεως της ουριας στο αιμα
PT966465E (pt) Inibidores do enzima imfdh
CY1111212T1 (el) Θειικες ενωσεις ως αναστολεις της πρωτεασης σερινης ns3 του ιου της ηπατιτιδας γ
EA200700117A1 (ru) N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
NO20074697L (no) Ikke-aromatisk, nitrogenholdig heterosyklisk-1-karboksylatester-pyridylderivat
BRPI0511111A (pt) compostos de pirrol como inibidores de cinase de proteìna de erk, sua sìntese e seus intermediários
EA200870019A1 (ru) Лактамовые соединения и способы их применения
ATE506456T1 (de) Verfahren zur behandlung von lentivirusinfektionen
EA200701257A1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
DE602004024572D1 (de) Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
WO2006034296A3 (en) Amino-containing compounds which inhibit memapsin 2 beta-secretase activity and methods of use thereof
ATE549404T1 (de) Verfahren zum screening eines transmembranenzymhemmstoffs
ATE435858T1 (de) Prodrugs von als erk-proteinkinase-inhibitoren wirkenden pyrrolylpyrimidinen
CY1110185T1 (el) Τροποποιημενη πρωτεϊνη vp1-καψιδιου του παρβοϊου β19
ATE550661T1 (de) Krebsdiagnose und behandlung unter verwendung eines anti-robo1-antikörper
DE602004012578D1 (de) Als inhibitoren von c-met geeignete pyrrolzusammensetzungen
NO20061575L (no) Fremgangsmate for fremstilling av renzapride og mellomprodukter derav
MA29554B1 (fr) Nouveaux derives d'amide d'acide piperidine carboxylique
DK1539724T3 (da) Aminobenzothiazolforbindelser med NOS-inhiberende aktivitet
WO2003099202A3 (en) Beta-secretase inhibitors